文献速递白血病淋巴瘤

靶向HDAC8通过降解HIF-1α使B细胞急性淋巴细胞白血病细胞对酪氨酸激酶抑制剂敏感

Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1α.
PubMed 文献 · Leukemia · 2025-09-02

研究发现Ph+ B-ALL患者样本经TKI处理后HDAC8高表达,抑制HDAC8可增强TKI对白血病细胞的清除并降低其致白血病能力;机制上HDAC8去乙酰化HIF-1α赖氨酸19/21位点,减缓HIF-1α降解;两种小鼠模型及患者来源异种移植模型中,靶向HDAC8或HIF-1α联合TKI显著抑制白血病进展。

要点

  • Ph+ B-ALL患者样本经TKI处理后HDAC8高表达。
  • 抑制HDAC8可增强TKI介导的白血病细胞清除并降低致白血病能力。
  • 靶向HDAC8/HIF-1α联合TKI在两种小鼠模型及PDX模型中显著抑制白血病进展。

核心结论

  • 靶向HDAC8/HIF-1α联合TKI可能是治疗Ph+ B-ALL的有前景策略。

研究设计与样本

  • 研究使用Ph+ B-ALL患者样本、两种小鼠模型及患者来源异种移植模型。

主要发现

  • Ph+ B-ALL患者样本经TKI处理后HDAC8高表达。
  • 抑制HDAC8显著增加TKI介导的白血病细胞清除并降低其致白血病能力。
  • 两种小鼠模型中TKI联合靶向HDAC8有效抑制白血病进展并降低干细胞频率。
  • 机制上HDAC8去乙酰化HIF-1α赖氨酸19/21位点,减少PHD2介导的羟化及随后的pVHL介导的泛素化,减缓HIF-1α降解。
  • 抑制HIF-1α诱导凋亡并降低白血病细胞的起始能力。

临床怎么用

  • 作者认为靶向HDAC8/HIF-1α联合TKI可能是治疗Ph+ B-ALL的有前景策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tyrosine kinase inhibitors (TKIs) only partially inhibit the growth of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) cells, and often lead to rapid relapse. Therefore, it is essential to elucidate the mechanisms of resistance and develop novel treatment strategies. Histone deacetylases (HDACs) are often dysregulated in hematological malignancies, and many HDAC inhibitors have shown potent antitumor activities. In this study, we found that HDAC8 was highly expressed in Ph+ B-ALL patient samples upon TKI treatment. HDAC8 inhibition significantly increased TKI-mediated elimination of leukemia cells and decreased their ability to initiate leukemia. Using two mouse models, we demonstrated that TKIs in combination with targeting HDAC8 effectively inhibited leukemia progression and reduced the frequencies of stem cells. Mechanistically, HDAC8 deacetylated hypoxia inducible factor-1α (HIF-1α) at lysine 19/21, leading to a reduction in PHD2-mediated hydroxylation and subsequent pVHL-mediated ubiquitination, which slowed the degradation of HIF-1α. HIF-1α inhibition induced apoptosis and decreased the initiating capacity of leukemia cells. Importantly, in a Ph+ B-ALL patient-derived xenograft model, targeting HDAC8 or HIF-1α in combination with TKIs significantly inhibited leukemia progression. In conclusion, our study revealed that targeting HDAC8/HIF-1α in combination with TKIs could be a promising strategy for treating Ph+ B-ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Xu G, Wang F, Chen M, et al. Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1α. Leukemia. 2025. PMID: 40897850. doi:10.1038/s41375-025-02749-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。